M. Sibille

Adverse events in phase-I studies: a report in 1015 healthy volunteers

M. Sibille, N. Deigat, Annick Janin et al. · European Journal of Clinical Pharmacology · 1998 · 87 citations

Adverse Events, Health Effect, Retrospective Cohort Study +9

A safety grading scale to support dose escalation and define stopping rules for healthy subject first‐entry‐into‐man studies

M. Sibille, Alain Patat, Henri Caplain et al. · British Journal of Clinical Pharmacology · 2010 · 30 citations · Full text

Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir System

Y. Le Roux, M. Borg, M. Sibille et al. · Clinical Drug Investigation · 1995 · 23 citations

Andrology, Urology, Bioavailability Study +5

Laboratory data in healthy volunteers: reference values, reference changes, screening and laboratory adverse event limits in Phase I clinical trials

M. Sibille, N. Deigat, I. Durieu et al. · European Journal of Clinical Pharmacology · 1999 · 18 citations

Clinical Trial Design, Medicine, Healthy Volunteers +10

Adverse events in phase one studies: a study in 430 healthy volunteers

M. Sibille, N. Deigat, V. Olagnier et al. · European Journal of Clinical Pharmacology · 1992 · 18 citations

Adverse Events, Health Effect, Adverse Event +10